Sargramostim

Also known as GM-CSF

Note: This product is not licenced in Australia at the time of publication. The information in this monograph applies to the specified brand, formulation, and strength only.

Trade name

Leukine

Presentation and preparation

Vial size (powder volume)	Fluid to add	Volume to add	Resulting concentration
250 microgram (negligible)	Water for injections	1 mL	250 microgram/mL

Reconstitute with 1 mL water for injections. Slowly add diluent towards the wall of the vial and swirl gently to mix. Do not shake. 

IV administration

Dilute with a compatible fluid to a minimum concentration of 10 microgram/mL. Do not shake. Give over 2 to 4 hours, or over 24 hours. Refer to local guidelines.

Other routes of administration

IM: Not recommended.

SC: Suitable. Give reconstituted solution undiluted.

Compatible IV fluids

Sodium chloride 0.9 %

Additional information

Observe closely for anaphylactic reactions.

Infusion related reactions: Respiratory distress, hypoxia, syncope, flushing, hypotension and/or tachycardia may occur following the first administration in a cycle and usually resolves with symptomatic treatment. Recurrence is unlikely in the same treatment cycle.

Acute symptoms such as dyspnoea may require a rate reduction of infusion by 50%. If symptoms persist or worsen after rate reduction, discontinue the infusion. Further infusions may be administered at standard doses with close monitoring.

Refrigerate, do not freeze.

Discard any unused vial contents.

Protect from light during storage.